Cerevance Media Center
Current News
November 27, 2017
Cerevance Appoints David H. Margolin, M.D., Ph.D., as Senior Vice President of Clinical and Translational Medicine
Prior to joining Cerevance, Dr. Margolin served in several leadership roles at Sanofi-Genzyme over a 14-year period. There, he leveraged his expertise in designing and leading translational medicine initiatives as well as clinical trials from phase 1 to phase 4 across various neurologic and rare disease indications...
October 24, 2017
Trailblazer in Molecular Genetics and Neuroscience, Jeremy Nathans, M.D., Ph.D., to Advise Cerevance
Dr. Nathans is Professor of Molecular Biology and Genetics, Neuroscience and Ophthalmology at the Johns Hopkins University School of Medicine in Baltimore, Maryland, where his research focuses on molecular mechanisms of visual system development, function, and disease. He is also an Investigator in the Howard Hughes Medical Institute.
October 17, 2017
Cerevance Licenses Human Brain Tissue Profiling Technology from The Rockefeller University
Cerevance, a drug discovery and development company focused on brain diseases, today announced that it has signed an agreement with The Rockefeller University to license a novel technology for profiling specific cell populations in human brain tissue
October 12, 2017
Harvard’s Rudolph Tanzi, Ph.D., a Leader in Alzheimer’s Disease Genetics, Joins Cerevance’s Advisory Board
Cerevance, a drug discovery and development company focused on brain diseases, today announced that Rudolph Tanzi, Ph.D., has joined the company as a senior-level scientific advisor.
News Archive
June 18, 2024
Cerevance Presents at The Federation of European Neuroscience Societies (FENS) Forum 2024
Cerevance to deliver a poster presentation at the upcoming Federation of European Neuroscience Societies (FENS) Forum 2024, taking place in Vienna, Austria, from June 25 – 29, 2024.
Ataxia-telangiectasia (A-T) is a rare neurodegenerative disease caused by mutations in the ataxia-telangiectasia mutated gene, leading to progressive neurological issues. Using Cerevance’s NETSseq platform, RNA from purified cerebellar cell types of A-T and control donors was analyzed and subsequently revealed significant astrocyte gene expression changes related to inflammation and immune response.
February 22, 2024
Cerevance to Participate at the TD Cowen 44th Annual Health Care Conference
December 5, 2023
Cerevance to Participate in Fireside Chat at the 2023 RBC Capital Markets Healthcare Private Company Virtual Conference
November 28, 2023
Cerevance Announces Presentation at the 34th International Symposium on ALS/MND
Events Archive
October 21, 2024
CVN424, a GPR6 Inverse Agonist, for Parkinson’s Disease and Motor Fluctuations: A Double-Blind, Randomized, Phase 2 Trial
June 30, 2021
Development of CVN424: A Selective and Novel GPR6 Inverse Agonist Effective in Models of Parkinson Disease
April 5, 2024
Discovery of CVN293, a Brain Permeable KCNK13 (THIK-1) Inhibitor Suitable for Clinical Assessment
February 15, 2023
Characterisation of C101248: A Novel Selective THIK-1 Channel Inhibitor for the Modulation of Microglial NLRP3-Inflammasome
Ossola, B., Rifat, A., Rowland, A., Hunter, H., Drinkall, S., Bender, C., Hamlischer, M., Teall, M., Burley, R., Barke, D., Cadwalladr, D., Dickson, L., Lawrence, J., Harvey, J., Lizio, M., Xu, X., Kavanagh, E., Cheung, T., Sheardown, S., Lawrence, C.B., Harte, M., Brough, D., Madry, C., Matthews, K., Doyle, K., Page, K., Powell, J., Brice, N.L., Bürli, R.W., Carlton, M.B., Dawson L.A.
Viewview